- Home
- USAS vs CELC Comparison
USAS vs CELC Comparison
Compare USAS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAS
- CELC
- Stock Information
- Founded
- USAS 1998
- CELC 2011
- Country
- USAS Canada
- CELC United States
- Employees
- USAS N/A
- CELC N/A
- Industry
- USAS Metal Mining
- CELC Medical Specialities
- Sector
- USAS Basic Materials
- CELC Health Care
- Exchange
- USAS Nasdaq
- CELC Nasdaq
- Market Cap
- USAS 386.9M
- CELC 440.0M
- IPO Year
- USAS N/A
- CELC 2017
- Fundamental
- Price
- USAS $0.79
- CELC $11.60
- Analyst Decision
- USAS Strong Buy
- CELC Strong Buy
- Analyst Count
- USAS 1
- CELC 5
- Target Price
- USAS $1.00
- CELC $30.80
- AVG Volume (30 Days)
- USAS 2.0M
- CELC 140.7K
- Earning Date
- USAS 08-14-2025
- CELC 08-13-2025
- Dividend Yield
- USAS N/A
- CELC N/A
- EPS Growth
- USAS N/A
- CELC N/A
- EPS
- USAS N/A
- CELC N/A
- Revenue
- USAS $102,883,000.00
- CELC N/A
- Revenue This Year
- USAS $45.78
- CELC N/A
- Revenue Next Year
- USAS $17.98
- CELC N/A
- P/E Ratio
- USAS N/A
- CELC N/A
- Revenue Growth
- USAS 8.12
- CELC N/A
- 52 Week Low
- USAS $0.21
- CELC $7.58
- 52 Week High
- USAS $0.88
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- USAS 62.02
- CELC 49.88
- Support Level
- USAS $0.77
- CELC $11.85
- Resistance Level
- USAS $0.86
- CELC $13.40
- Average True Range (ATR)
- USAS 0.06
- CELC 0.70
- MACD
- USAS 0.00
- CELC -0.09
- Stochastic Oscillator
- USAS 68.37
- CELC 35.83
About USAS Americas Gold and Silver Corporation no par value
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.